Product Description: Pivekimab is a human IgG1 monoclonal antibody targeting interleukin 3 (IL-3) and CD123. Pivekimab can be used in the study of blastocytic plasmacytoid dendritic cell tumor (BPDCN)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533.